AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
2.850
+1.140 (66.67%)
At close: Mar 6, 2026, 4:00 PM EST
2.758
-0.092 (-3.23%)
After-hours: Mar 6, 2026, 7:59 PM EST
AN2 Therapeutics Employees
AN2 Therapeutics had 22 employees as of December 31, 2024. The number of employees decreased by 19 or -46.34% compared to the previous year.
Employees
22
Change (1Y)
-19
Growth (1Y)
-46.34%
Revenue / Employee
n/a
Profits / Employee
-$1,544,818
Market Cap
78.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | -19 | -46.34% |
| Dec 31, 2023 | 41 | 5 | 13.89% |
| Dec 31, 2022 | 36 | 14 | 63.64% |
| Dec 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Pliant Therapeutics | 171 |
| Adicet Bio | 152 |
| Seres Therapeutics | 103 |
| Fractyl Health | 101 |
| PolyPid | 73 |
| Verrica Pharmaceuticals | 71 |
| aTyr Pharma | 65 |
ANTX News
- 4 days ago - AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Business Wire
- 18 days ago - AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference - Business Wire
- 7 weeks ago - AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease - Business Wire
- 4 months ago - AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 4 months ago - AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - Business Wire
- 4 months ago - AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference - Business Wire
- 7 months ago - AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 7 months ago - AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease - Business Wire